Mostrando 4 resultados de: 4
Filtros aplicados
Publisher
Cancer Biology and Therapy(1)
Clinical Cancer Research(1)
Journal of Immunotherapy(1)
Seminars in Oncology(1)
Área de conocimiento
Farmacología(1)
Origen
scopus(4)
Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck
ArticleAbstract: The prognosis of patients with advanced head and neck cancer remain dismal. For this tumor type, elePalabras claves:Epidermal growth factor receptor, immunotherapy, Monoclonal antibody, nimotuzumab, Squamous cell carcinoma of the head and neck, Targeted therapyAutores:Alert J., Bahi R.D.C., Bárbara Wilkinson, Bilbao M.A., Carmen Elena Viada, De Armas E.L., Frómeta M., Galainena J.J., Gracias E., Iznaga N., Leonard I., Luaces P.L.o., Muchuli C.R., Mulén B., Mullens V., Pérez K., Pineda I., Rivero T.C., Rodríguez E., Rodríguez M.O., Tania Crombet, Torres O., Vinageras E.N.Fuentes:scopusNimotuzumab: beyond the EGFR signaling cascade inhibition
ReviewAbstract: One of the most known oncogenes is the epidermal growth factor receptor (EGFR) family. It activatesPalabras claves:antibody-dependent cell mediated cytotoxicity (ADCC), eGFR, HLA class I molecules, monoclonal antibodies, Natural killer cells, T cellsAutores:Chao L., Iznaga N., Lavastida A., Mazorra Z., Ramos M., Sanchez B., Tania CrombetFuentes:scopusPharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: A SENDO Foundation study
ArticleAbstract: Purpose: To assess the pharmacodynamic effects of nimotuzumab, an anti-epidermal growth factor recepPalabras claves:Autores:Albanell J., Bellosillo B., Campas C., Cedeño M., Corominas J.M., Corradino I., Cruz T., Gascon P., Gracias E., Iznaga N., Marsoni S., Osorio M., Rojo F., Rovira A., Serrano S., Sessa C., Tania Crombet, Villena N.Fuentes:scopusPharmacological Evaluation of Humanized Anti-Epidermal Growth Factor Receptor, Monoclonal Antibody h-R3, in Patients With Advanced Epithelial-Derived Cancer
ArticleAbstract: Epidermal growth factor receptor (EGFR) overexpression has been detected in many tumors of epitheliaPalabras claves:Epidermal growth factor receptor, Monoclonal antibody, Phase I clinical trialAutores:Catala M., Iznaga N., Lage Davila A., Neninger Vinageras E., Perera A., Pérez R., Solano M., Tania Crombet, Torres F., Torres L., Torres O.Fuentes:scopus